Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules

Cystic Fibrosis Clinical Trial

Official title:

A Multicenter, Human Factors Validation Study in Cystic Fibrosis Patients Aged 6 Years and Older to Evaluate the User Interface of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03502070
• Other study ID #: CTBM100C2419
• Status: Completed
• Phase: Phase 4
• Start date: June 26, 2018
• Est. completion date: June 17, 2019

Study information

• Verified date: March 2022
• Source: Viatris Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to validate the user interface of TOBI Podhaler by establishing that the product can support safe and effective use for the intended users

Description:

The objective is to conduct a human factors validation study to demonstrate that the user interface of TOBI® Podhaler™ can support safe and effective use for the intended users. The human factors validation study will be conducted in patients with cystic fibrosis aged 6 years and older under simulated yet representative of realistic use conditions where patients with no prior training or use of TOBI® Podhaler™ will be asked to inhale the contents of placebo capsules through the Podhaler device. Due to the use of placebo capsules, the study is considered an interventional clinical study and will be conducted accordingly. The study is an open label, un-blinded, non-randomized study which consists of one visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 47
• Est. completion date: June 17, 2019
• Est. primary completion date: March 19, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent or, parent/guardian consent and where applicable pediatric assent, must be obtained before any assessment is performed

• Male and female subjects aged 6 years and older

• Confirmed diagnosis of CF by one or more of the following tests for CF as documented in the patient's medical history : (1) quantitative pilocarpine iontophoresis sweat chloride test of > 60 mmol/L or 60 mEq/L, (2) genotype with identifiable CF-causing mutations on both chromosomes, (3) an abnormal nasal transepithelial potential difference characteristic of CF

• FEV1 value must be at least 25% of normal predicted values for age, sex, and height as documented in the patient's medical history (historical values within 3 months can be used for this criterion).

• Able to comply with all protocol requirements

• Clinically stable in the opinion of the investigator

Exclusion Criteria:

• Subjects currently enrolled in studies that are not considered as observational non-investigational studies

• Subjects or caregivers who have used the Podhaler device previously

• Hemoptysis more than approximately 60 mL at any time within 30 days prior to enrollment

• History of hypersensitivity to the inhaled placebo dry powder (DSPC and/or calcium chloride powder)

• Signs and symptoms of acute pulmonary disease, e.g. pneumonia, pneumothorax, bronchospasm, acute respiratory infection

• Clinically significant conditions or findings at enrollment that might interfere with the accurate and valid assessment of this study

• Subjects or caregivers who are considered potentially unreliable or considered unlikely to be compliant within the trial

• Pregnant women

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis

Intervention

Drug:
• Placebo
One dose (4 capsules) of placebo

Device:
• Tobi Podhaler
The placebo capsule has to be released from the blister card and inserted into the Podhaler device. The device is then actuated and the study drug is inhaled according to the instructions for use

Locations

Country	Name	City	State
United States	Batchelor Childrens Research Institute	Miami	Florida
United States	University of Miami Hospital	Miami	Florida
United States	Tulane Lakeside Hospital for Women and Children	New Orleans	Louisiana
United States	Respiratory Diseases of Children and Adolescents	Oklahoma City	Oklahoma
United States	University of Oklahoma Health Science Center	Oklahoma City	Oklahoma
United States	Nemours Childrens Hospital	Orlando	Florida
United States	Nemour's Children's Clinic - Pensacola	Pensacola	Florida
United States	VCU Children's Pavilion	Richmond	Virginia
United States	Toledo Childrens Hospital	Toledo	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Mylan Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Critical Use Errors and Close Calls Associated With the Simulated Inhalation of One Dose Using TOBI Podhaler	Critical use errors and close calls for the following: placing of capsule into the top of the mouthpiece, failure to replace mouthpiece, failure to adequately pierce capsule, failure to release before inhaling, multiple piercing of capsule, exhalation into mouthpiece, inadequate seal around mouthpiece, inadequate inhalation technique, failure to use reserve device when capsule not adequately pierced, failure to administer 4 capsules per dose, swallowing of capsule	1 Day